Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 1:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adults With Ulcerative Colitis Clear all
Completed Not applicable Interventional

A Clinical Study to Assess the Effects of KB295 in Patients With Ulcerative Colitis (UC) on Gut Microbiota Structure and Function

NCT04508413
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
KB295
Other
Lead sponsor
Kaleido Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Jun 27, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis

NCT01694485
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Abrilumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
25
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Jun 27, 2026, 1:51 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

NCT07463183
View directory record Official record
Conditions
Colitis Ulcerative, Ulcerative Colitis
Interventions
MK-8690, Placebo
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Anaheim, California • Colorado Springs, Colorado • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 27, 2026, 1:51 AM EDT
Recruiting Phase 2 Interventional

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

NCT07483073
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Oxnard, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 27, 2026, 1:51 AM EDT
Terminated Phase 1 Interventional

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

NCT05549323
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PF-07054894, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Kissimmee, Florida • Tampa, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jun 27, 2026, 1:51 AM EDT
Active, not recruiting Phase 3 Interventional

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

NCT02914535
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Filgotinib, Placebo
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
1,173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
57
States / cities
Dothan, Alabama • Scottsdale, Arizona • Long Beach, California + 49 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 27, 2026, 1:51 AM EDT
Terminated Phase 1 Interventional

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

NCT03923478
View directory record Official record
Conditions
Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate
Interventions
ABI-M201, Placebo
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
Oakland, California • San Carlos, California • Decatur, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Jun 27, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis

NCT02914522
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Filgotinib, PTM filgotinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
61
States / cities
Dothan, Alabama • Scottsdale, Arizona • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Jun 27, 2026, 1:51 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)

NCT05466890
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative, Ulcerative Colitis Flare
Interventions
PL8177 Placebo, PL8177
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Tucson, Arizona • Lancaster, California • Tarzana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Jun 27, 2026, 1:51 AM EDT
Recruiting Phase 4 Interventional

A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting

NCT06581328
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab IV, Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jun 27, 2026, 1:51 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

NCT02520284
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Andecaliximab, Placebo
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
33
States / cities
Dothan, Alabama • Wheat Ridge, Colorado • Lauderdale Lakes, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Jun 27, 2026, 1:51 AM EDT
Not yet recruiting No phase listed Observational

A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease

NCT07250815
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
No intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
65 Years and older
Enrollment
23,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 27, 2026, 1:51 AM EDT
Completed Not applicable Interventional Results available

Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease

NCT00791557
View directory record Official record
Conditions
Pyoderma Gangrenosum, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Infliximab
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 27, 2026, 1:51 AM EDT
Completed Not applicable Interventional

Trial of a Decision Support Intervention for Adolescents and Young Adults With Ulcerative Colitis

NCT04207008
View directory record Official record
Conditions
Ulcerative Colitis, Pediatric
Interventions
iBDecide Decision Support Application
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
14 Years to 25 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Jun 27, 2026, 1:51 AM EDT
Recruiting Phase 2 Interventional

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

NCT07415044
View directory record Official record
Conditions
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Interventions
LY4268989, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
49
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 27, 2026, 1:51 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Risankizumab, Vedolizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
74
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 65 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 27, 2026, 1:51 AM EDT
Not yet recruiting Phase 4 Interventional

Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis

NCT07059130
View directory record Official record
Conditions
Crohn Disease (CD), Crohns Disease, Ulcerative Colitis (UC)
Interventions
Mirikizumab
Biological
Lead sponsor
Rubix LS
Industry
Eligibility
60 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Jun 27, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

NCT05570006
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ABBV-668
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Chula Vista, California • Maitland, Florida • Margate, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jun 27, 2026, 1:51 AM EDT
Recruiting Phase 3 Interventional

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086
View directory record Official record
Conditions
Ulcerative Colitis, Obesity or Overweight
Interventions
Mirikizumab, Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
Dothan, Alabama • Anaheim, California • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 27, 2026, 1:51 AM EDT
Recruiting Phase 2 Interventional

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic
Interventions
Eltrekibart, Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
46
States / cities
Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 27, 2026, 1:51 AM EDT
Completed Not applicable Interventional

Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease

NCT00114803
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Calcitonin nasal spray (salmon)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 22 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2007 · Synced Jun 27, 2026, 1:51 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

NCT04254783
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn's Disease
Interventions
Risankizumab, Cytochrome P450 (CYP) Substrates
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Coronado, California • DeLand, Florida • Margate, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Jun 27, 2026, 1:51 AM EDT
Recruiting Phase 3 Interventional

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Icotrokinra, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
54
States / cities
Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 27, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

NCT04090411
View directory record Official record
Conditions
Moderate to Severe Ulcerative Colitis
Interventions
Induction- PF-06480605 50 mg SC Q4W, Induction- PF-06480605 150 mg SC Q4W, Induction- PF-06480605 450 mg SC Q4W, Induction- Placebo SC Q4W, Chronic- PF-06480605 50 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 450 mg SC Q4W
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
55
States / cities
Dothan, Alabama • Little Rock, Arkansas • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jun 27, 2026, 1:51 AM EDT